PDF
(Download)
|
- Turmeric (Curcuma longa)
- Curcumin
- Major Depressive Disorder
|
Date:
09-13-2013 | HC# 081361-480
|
Re: Clinical Trial Demonstrates that a Standardized Curcumin Product Is Efficacious in Treating Major Depressive Disorder
Sanmukhani
J, Satodia V, Trivedi J, et al. Efficacy and safety of curcumin in major
depressive disorder: a randomized controlled trial. Phytother Res. 2013; [epub ahead of print]. doi: 10.1002/ptr.5025.
Depression
affects many people throughout the world and can be the cause of disruptive
health problems, and can even lead to suicide. Although standard pharmaceutical
treatments exist, chronic use of them may result in adverse effects. Botanicals
may provide therapeutic options for depression with greater tolerability. Curcumin,
a compound found in turmeric (Curcuma
longa) root, has been shown to alleviate depression previously; suggested
mechanisms include impacts on neurotransmitters and the potentiation of other
antidepressant pharmaceuticals. This 6-week, randomized, controlled trial
investigated curcumin, the standard antidepressant fluoxetine, and a
combination of both treatments in patients suffering from major depressive
disorder (MDD).
Patients
diagnosed with MDD were recruited at Sir Takhtasinhji General Hospital in
Bhavnagar, Gujarat, India. Patients were older than 18 years of age, had access
to a caregiver, and rated higher than 7 on the Hamilton Depression Rating Scale
(17-item version; HAM-D17). This scale rates symptoms of depression,
and total scores of 0-7 are considered normal. Those suffering from other
severe mental illness, including those with suicidal tendencies, seizures,
thyroid disorders, or allergies to the study treatments, were excluded. Those
for whom at least 2 other antidepressants had failed to work, those who had
taken antidepressants or an "investigational" drug within 30 days
prior to the study, and those who were participating in therapy were excluded.
Included female patients were using contraception and were not pregnant at the
time of the study's beginning.
Curcumin
(50-mg capsules) was procured from Arjuna Natural Extracts; Kochi, Kerala,
India. Capsules were standardized to contain 88% curcuminoids and 7% volatile
oils, and the daily dose of curcumin was 1000 mg. Fluoxetine (20-mg capsules of
Flunil-20®) was obtained from Intas Pharmaceuticals; Ahmedabad, Gujarat,
India. The fluoxetine dosage was 20 mg per day. Prior to being randomly
assigned, patients were subjected to physical and psychiatric exams, laboratory
parameters, and vital sign measurements. Patients were randomly assigned to
groups taking either fluoxetine only, curcumin only, or both fluoxetine at 20
mg/day and curcumin at 1000 mg/day, for 6 weeks. Curcumin was administered
twice daily, 12 hours apart, in 500-mg doses taken after breakfast and dinner.
During the first 2 weeks of the study, paracetamol and benzodiazepines were
permitted to treat headaches and insomnia, respectively. At 2, 4, and 6 weeks
into the study, parameters were measured.
The
primary outcome was the HAM-D17 score, followed by the mean change
in the score and the remission rate. Secondary outcomes included patients' rate
of response on the Clinical Global Impression-Improvement (CGI-I) assessment scale
and scores on the Clinical Global Impression-Severity of Illness (CGI-S) scale.
The CGI-I is a 7-point scale where 1 means "very much improved" and 7
means "very much worse"; and the CGI-S is a 7-point scale where 1
means "normal/not at all ill" and 7 means "extremely ill."
Safety was assessed by treatment-emergent adverse events (TEAEs), the
measurement of vital signs, and physical exams during clinical visits.
Laboratory parameters were also measured at the end of the study. Those with a
HAM-D17 score of ≤ 7 were considered to be in remission; a 50%
decline in HAM-D17 scores as compared with baseline scores
constituted a response. According to the CGI-I scale, a score of 1 or 2
indicated a response. Efficacy and tolerability were classified as "excellent,
good, fair, or poor." Pill counting was done to assess compliance.
Of
the patients recruited, 60 were enrolled and were randomly assigned to the 3
groups (n=20 per group). Overall, there were no "major" deviations or
violations of the protocol. Because of either loss to follow-up or withdrawal
due to adverse effects (fluoxetine group), 45 patients completed the study,
with 16 in the fluoxetine group, 14 in the curcumin group, and 15 in the
combination group for the per-protocol analysis (the intention-to-treat [ITT]
population was n=17 in the fluoxetine group, n=16 in the curcumin group, and
n=18 in the combination group). According to the HAM-D17, a greater
response to treatment in the ITT population was observed in the combination
group compared to the curcumin group and the fluoxetine group; this was not
significantly different (77.8% vs. 62.5% and 64.7%, respectively; P=0.58).
At
the end of the study, the mean changes in the HAM-D17 scores in the
ITT population were not significantly different between the combination group
(-14.8; 95% confidence interval [CI]: -17.6, -12.0) and the fluoxetine group
(-14.0; 95% CI: -18.2, -9.8) or the curcumin group (-12.6; 95% CI: -15.8, -9.5;
P=0.77). This was also true of the rate of remission (P=0.58), and the results
were the same in the per-protocol analysis. The efficacy rating was either
"excellent" or "good" for 70.5% of those in the fluoxetine
group, 75% of those in the curcumin group, and 83.3% of those in the
combination group; there were no significant differences between them (P=0.66).
TEAEs
were observed in 2 patients in the fluoxetine group, 2 in the curcumin group,
and 5 in the combination group. Adverse effects were classified as
"mild" and included gastritis, giddiness, hot flashes, nausea,
photosensitivity, and mouth ulcers. No significant differences were seen at the
end of the study as compared to baseline in patients' laboratory or physical
parameters. Although tolerability was rated as "excellent" for 82.3%
of those in the fluoxetine group and 87.5% of those in the curcumin group as
compared with 66.6% of those in the combination group, these differences were
not significant (P=0.30).
This
study showed curcumin to have similar efficacy as fluoxetine. It is suggested
that curcumin's bioactivity may be due to effects on neurotransmitters such as
serotonin, or the concurrent potentiation of antidepressant pharmaceuticals.
This study also shows curcumin to be well tolerated, with no serious adverse
effects. It is discussed that curcumin's bioavailability was improved through
the addition of curcuminoids and volatile oils, although this additive process
is not described in the methods. Discussed shortcomings of this trial include
the intentionally small sample size and the absence of a placebo group. Also,
patients were not blinded to the treatments. A future, double-blind,
placebo-controlled clinical trial will likely confirm curcumin as a good
candidate for the treatment of MDD, both alone and in combination with standard
treatments.
—Amy C. Keller,
PhD
|